BioEP is a seizure susceptibility assessment technology that can provide objective support to clinicians enabling faster and more accurate diagnosis and prognosis of epilepsy.
Epilepsy is a serious neurological condition that impacts over 65M people around the world.
BioEP is a patented seizure risk score calculated from routine EEG recordings that can enable faster and more accurate diagnosis and prognosis of epilepsy.
Neuronostics is a collaborative organisation and welcomes enquiries from researchers, clinicians and commercial partners.
Neuronostics is a fast growing med-tech company, passionate about using research to improve the lives of people with epilepsy.
We are developing a novel and potentially revolutionary seizure susceptibility assessment technology called #BioEP.
Our goal at Neuronostics is to improve the quality of life of people with epilepsy, those suspected of having epilepsy and those family and friends who share their lives with them.
We are working in partnership with members of the public, people with epilepsy, special interest groups, researchers, doctors and neurologists, to bring the benefits of #BioEP to the wider community globally.
5 October 2021 On Friday evening, we were delighted to once again attend Medilink UK’s awards. This time to find out how #ConnectEP, shortlisted for innovation, would fare at the national level.... [Read More]
We’re looking for someone to join our team as a Business Development Manager! You’ll want to be in a Business Development role with meaning – by providing our team at Neuronostics with... [Read More]
24 June 2021 We are today able to share that we are one of the final four in the global Nature Spinoff Prize 2021! The finalists were chosen for their potential to... [Read More]